コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ent L1 isoforms during the natural course of papillomavirus infection.
2 Cervical cancer is caused by human papillomavirus infection.
3 ctrochemical signal corresponded to a bovine papillomavirus infection.
4 immunoregulatory control of oncogenic human papillomavirus infection.
5 surface receptor(s) is a subsequent step of papillomavirus infection.
6 hat recapitulates the establishment phase of papillomavirus infection.
7 n papillomaviruses in the context of in vivo papillomavirus infection.
8 represents the epithelial response to human papillomavirus infection.
9 ounds that might block the initial stages of papillomavirus infection.
10 pproval of vaccines to prevent initial human papillomavirus infection.
11 year post-BMT, 71% developed chronic canine papillomavirus infection.
12 ins have been shown to protect against human papillomavirus infection.
13 n against E2 protein using a rabbit model of papillomavirus infection.
14 effective strategy for immunoprophylaxis of papillomavirus infection.
15 human anogenital carcinomas show evidence of papillomavirus infection.
16 n globally, often linked to persistent human papillomavirus infection.
17 eled to recognize the signs of genital human papillomavirus infection.
18 sen rapidly, because of an epidemic of human papillomavirus infection.
19 us SCC, given their common etiology in human papillomavirus infection.
20 ctions with molluscum contagiosum; and human papillomavirus infections.
21 keratin 17, which promotes immune evasion in papillomavirus infections.
25 nteraction is predicted to impede persistent papillomavirus infection and consequently provides a nov
27 ighly active antiretroviral therapy on human papillomavirus infection and its related anogenital abno
28 be associated with lower genital tract human papillomavirus infection and may have implications in th
29 high total cholesterol, hypertension, human papillomavirus infection and related pre-cancerous stage
30 s have reported an association between human papillomavirus infection and subsequent cervical dysplas
31 healthy participants at risk for oral human papillomavirus infection and the agreement with oral rin
32 inue to confirm the high prevalence of human papillomavirus infection and to define the different hum
33 ccine platforms for both prevention of human papillomavirus infection and treatment of associated dis
36 pendent signaling pathway in the response to papillomavirus infections and the progression of these v
37 tals, and environmental tobacco smoke, human papillomavirus infection, and inherited genetic suscepti
38 high total cholesterol, hypertension, human papillomavirus infection, and related precancerous stage
39 iabetes, hypertension, hyperlipidemia, human papillomavirus infection, and tobacco use disorder using
40 ighly active antiretroviral therapy on human papillomavirus infection; and novel human papillomavirus
42 experimental data implicate cutaneous human papillomavirus infection as co-factor in the development
43 viral therapy era, raising concerns of human papillomavirus infections as a rising health burden amon
44 al neutralizing antibody can protect against papillomavirus infection at both cutaneous and mucosal s
45 ody (MPV.A4) by passive immunization against papillomavirus infections at both cutaneous and mucosal
48 nome integration.IMPORTANCE Persistent human papillomavirus infections can cause a variety of signifi
51 n of the association of cervical cancer with papillomavirus infection encouraged development of a vac
52 .9% (95% CI: 24.3-43.5%) for high-risk human papillomavirus infection from cervical samples and 78.6%
53 n cleavage of minor capsid protein L2 during papillomavirus infection has been difficult to directly
54 evious studies examining the pathogenesis of papillomavirus infections have relied on the use of orga
55 amous cell carcinoma (HNSCC) caused by human papillomavirus infection (HPV(+)), patients have transcr
57 maviruses are widely used as models to study papillomavirus infection in humans despite differences i
59 alizing antibody can protect against diverse papillomavirus infections in a time-dependent manner in
60 s (MmuPV1) provides the opportunity to study papillomavirus infections in vivo in the context of a co
69 mycobacterial, bacterial, fungal, and human papillomavirus infections, lymphedema, pulmonary alveola
72 fidence interval (CI): 2.4, 23.2), any human papillomavirus infection (OR = 5.8; 95% CI: 3.3, 10.0),
73 included HIV-1 infection (p = 0.013), human papillomavirus infection (p=0.0013), lower CD4 T lymphoc
74 ytological assay were used to look for human papillomavirus infection, p53 mutations, loss of heteroz
75 his is analogous to the late-onset cutaneous papillomavirus infection recently described for human XS
77 tigated the extent to which animal models of papillomavirus infection resemble human disease by compa
78 ical features, including age, sex, and human papillomavirus infection status, were collected for a ba
79 hain reaction-based tests for cervical human papillomavirus infection, tests for gonorrhea and chlamy
80 uggest that the natural progression of human papillomavirus infection, the causal agent in all cervic
85 differences in the natural history of human papillomavirus infections; the effect of highly active a
86 main risk factor for anal cancer is a human papillomavirus infection; those with chronic immunosuppr
88 tigate the potential effect of EVER genes on papillomavirus infection, we pursued in vivo infection s